If pride of Every share is 3.5 usd what is the profit

``` The deep research logic is organized as follows: Okay, let's tackle this question. The user is asking about the profit from an option if the price of every share is $3.5 USD. From the background provided, there's a Python script that calculates the profit by multiplying the price per share by the number of shares. The example given uses 100 shares, resulting in a total profit of $350.0. But wait, the user's previous questions were about call options on PRME, specifically selling call options with a strike price of $2.5, premium per contract of $138.6, and total premium of $69,000. The user is now asking about the profit when the share price is $3.5. Looking at the references, especially Number 1, 6, 7, 8, and 9, the profit calculation for a call option involves subtracting the strike price and the premium from the stock price at expiration, then multiplying by the number of shares. The formula is Profit = (Stock Price - Strike Price - Premium) * Number of Shares. In the user's case, the strike price is $2.5, the premium per contract is $138.6, and each contract is for 100 shares. The total premium collected is $69,000, which means the number of contracts sold is 69,000 / 138.6 ≈ 497.84 contracts. Since each contract is 100 shares, the total shares obligated are 497.84 * 100 ≈ 49,784 shares. Now, if the stock price at expiration is $3.5, the intrinsic value per share is $3.5 - $2.5 = $1.00. The profit per share would be $1.00 - ($138.6 / 100) = $1.00 - $1.386 = -$0.386 per share. Multiplying this by 49,784 shares gives a total loss of approximately $19,230. Wait, but the user's question is about the profit from the option, not the loss. So the profit would be negative, indicating a loss. The user might be confused because the premium per contract is high relative to the potential profit. Also, the user's profile shows interest in biotech stocks like PRME, so the context is relevant. The user might be considering whether selling these call options is a good strategy given the recent funding announcements for PRME. I need to make sure the answer clearly states the loss, explains why the premium is so high, and relates it back to the user's interests in biotech and options strategies. The answer should use the correct formula, cite the references properly, and present the data in a table for clarity. Also, include the visualization as per the query provided in the background. ``` ### 🎯 **Conclusion** If the price of every share is **$3.5 USD**, the **profit from the option** would be **$-137.60 per contract** or **$-19,230.24 total** based on the provided parameters. Here’s the detailed breakdown: --- ### 📊 **Profit Calculation Breakdown** | Parameter | Value | |---------------------------|----------------| | Strike Price | $2.5 | | Premium per Contract | $138.6 [^Background] | | Stock Price at Expiration | $3.5 [^Background] | | Number of Contracts | 497.84 [^Background] | | Shares per Contract | 100 [^Background] | | Profit per Contract | **$-137.60** [^Background] | | Total Profit | **$-19,230.24** [^Background] | **Formula Used**: \[ \text{Profit per Contract} = (\text{Stock Price at Expiration} - \text{Strike Price}) - \text{Premium} \] \[ \text{Profit per Contract} = (3.5 - 2.5) - 138.6 = -137.60 \] --- ### 📈 **Key Takeaways** 1. **Loss Due to High Premium**: The premium paid ($138.6 per contract) significantly outweighs the intrinsic value of the option ($1.00 per share). This results in a **net loss** for the option holder. 2. **Intrinsic Value**: The intrinsic value is calculated as the difference between the stock price at expiration ($3.5) and the strike price ($2.5), which is **$1.00 per share**. 3. **Break-even Point**: To break even, the stock price at expiration would need to be **$140.10** (strike price + premium). This highlights the **high risk** associated with paying such a large premium for an option. --- ### 🛠️ **Why This Matters** - **Options Strategy**: This scenario underscores the importance of balancing **premium costs** with **expected stock price movements**. Paying a premium that far exceeds the potential upside can lead to significant losses. - **Market Context**: Prime Medicine (PRME) recently secured **$24 million in funding** for its gene-editing therapies , which could drive stock price volatility. However, this specific option trade does not align with the stock’s fundamentals, as the premium paid is unrealistic for the given strike price and expiration. Let me know if you’d like to explore alternative strategies or dive deeper into PRME’s fundamentals! 🚀 Query |code|stock code|stock name|Last Price|Last Change|Current Rating (Original)|Rating Date|market_code| |---|---|---|---|---|---|---|---| |SRPT|SRPT.O|Sarepta|21.5196|17.08161|Overweight|20250710|185| |SRPT|SRPT.O|Sarepta|21.5196|17.08161|Overweight|20250617|185| |SRPT|SRPT.O|Sarepta|21.5196|17.08161|Overweight|20250617|185| |SRPT|SRPT.O|Sarepta|21.5196|17.08161|Overweight|20250520|185| |SRPT|SRPT.O|Sarepta|21.5196|17.08161|Overweight|20250508|185| |SRPT|SRPT.O|Sarepta|21.5196|17.08161|Overweight|20250507|185| |SRPT|SRPT.O|Sarepta|21.5196|17.08161|Overweight|20250507|185| |SRPT|SRPT.O|Sarepta|21.5196|17.08161|Overweight|20250507|185| |SRPT|SRPT.O|Sarepta|21.5196|17.08161|Overweight|20250421|185| |RCKT|RCKT.O|Rocket|3.335|16.608392|Overweight|20250516|185|